A constant supply of bad news is jeopardizing the long-term sales of Tylenol and other Johnson & Johnson (NYSE: JNJ) products, says Motley Fool columnist Brian Orelli. "Contrary to the popular saying, there is such a thing as bad press and if you're getting it month after month, it's even worse." If J&J can't overcome the negative image quickly, he says, consumers will head to competing brand-name drugs or just grab generics. They also make take more direct action: Consumers are accusing the drugmaker of fraud and racketeering in a lawsuit stemming from the recent recall, and demanding cash refunds rather than replacement coupons. Column | Article